Multispecific Antibodies: Key Challenges And Solutions To Enable A New Frontier In Cancer Treatment

Monoclonal antibodies (mAbs) have been a key therapeutic pillar in cancer treatment, yet their conventional "one-drug-one-target" approach faces limitations against the inherent adaptiveness and complexity of tumors, especially in solid tumors. Multispecific antibodies (msAbs), including bispecific antibodies (bsAbs), are emerging as a potent next-generation response, designed to target multiple signaling pathways and overcome resistance mechanisms.

The development of these advanced therapeutics introduces significant hurdles, including complex molecule design, lower expression titers, and chain mispairing during manufacturing. Furthermore, developers must navigate a rapidly evolving regulatory landscape that lacks established playbooks. Success hinges on adopting a comprehensive, integrated framework that aligns discovery, cell line development, and manufacturing early on. Explore the critical challenges and solutions, like utilizing stable CHO cell lines and transposon-based vector integration, that are accelerating the path from concept to clinic.